NasdaqGS - Nasdaq Real Time Price USD
CARGO Therapeutics, Inc. (CRGX)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 4:02 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -1.13 | -1.23 | -4.27 | -4.66 |
| Low Estimate | -1.45 | -2.01 | -5.31 | -6.16 |
| High Estimate | -0.99 | -0.93 | -3.88 | -3.44 |
| Year Ago EPS | -47.37 | -1.49 | -16.53 | -4.27 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -- | -- | -- | 830k |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 5M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -2.78 | -1.44 | -1.05 | -1.03 |
| EPS Actual | -47.37 | -1.49 | -0.87 | -1.02 |
| Difference | -44.59 | -0.05 | 0.18 | 0.01 |
| Surprise % | -1,604.00% | -3.50% | 17.10% | 1.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.13 | -1.23 | -4.27 | -4.66 |
| 7 Days Ago | -1.13 | -1.23 | -4.27 | -4.66 |
| 30 Days Ago | -1.13 | -1.23 | -4.27 | -4.66 |
| 60 Days Ago | -1.13 | -1.23 | -4.27 | -4.66 |
| 90 Days Ago | -1.15 | -1.34 | -4.41 | -4.7 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CRGX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 97.60% | -- | -- | 3.70% |
| Next Qtr. | 17.40% | -- | -- | 7.90% |
| Current Year | 74.20% | -- | -- | 2.50% |
| Next Year | -9.10% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.88% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/13/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 8/13/2024 |
| Initiated | HC Wainwright & Co.: Buy | 7/22/2024 |
| Initiated | Chardan Capital: Buy | 7/8/2024 |
| Initiated | Piper Sandler: Overweight | 6/27/2024 |
| Reiterates | Truist Securities: Buy to Buy | 5/16/2024 |
Related Tickers
SYRE Spyre Therapeutics, Inc.
32.76
0.00%
MLYS Mineralys Therapeutics, Inc.
14.40
+3.75%
CGEM Cullinan Therapeutics, Inc.
16.77
-3.45%
BCAX Bicara Therapeutics Inc.
21.96
+7.44%
IRON Disc Medicine, Inc.
50.56
+0.14%
COGT Cogent Biosciences, Inc.
11.90
+2.23%
NGNE Neurogene Inc.
54.40
+2.80%
AVBP ArriVent BioPharma, Inc.
29.16
+0.59%
ACLX Arcellx, Inc.
96.86
+1.67%
CGON CG Oncology, Inc.
36.44
-0.87%